Notably, Niraparib, a potent PARP inhibitor, was authorized for advanced ovarian cancer regardless of homologous recombination (HR, a high-fidelity DNA repair mechanism) status, underscoring its broad therapeutic potential [3,4]. The gene discussed is PARP1; the disease is ovarian cancer.